Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs. placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer - Rugo, H S; Schmid, P; Cescon, D W (San Antonio Breast Cancer Symposium, 2020)
Accessed March 16 2021 at: